Pharsight

1. List of Zydelig drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44638	GILEAD SCIENCES INC	Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta	Aug, 2025 (2 years from now)
US8865730	GILEAD SCIENCES INC	Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one	Mar, 2033 (10 years from now)
US10730879	GILEAD SCIENCES INC	Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one	Mar, 2033 (10 years from now)
US9469643	GILEAD SCIENCES INC	Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one	Sep, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980901	GILEAD SCIENCES INC	5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta	May, 2025 (2 years from now)
US9149477	GILEAD SCIENCES INC	5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta	May, 2025 (2 years from now)
USRE44599	GILEAD SCIENCES INC	Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta	Jul, 2025 (2 years from now)
US9492449	GILEAD SCIENCES INC	Therapies for hematologic malignancies	Mar, 2030 (7 years from now)

Market Authorisation Date: 23 July, 2014

Treatment: For the treatment of patients with cll, fl, or sll; Inhibition on pi3k kinase; For the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll)

Dosage: TABLET;ORAL